NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Stock Information for Neuropace Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Neuropace Inc.

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
NeuroPace to Participate in Upcoming Healthcare Conferences
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.